-$0.44 EPS Expected for Catalyst Biosciences, Inc. (NASDAQ:CBIO) This Quarter

Analysts forecast that Catalyst Biosciences, Inc. (NASDAQ:CBIO – Get Rating) will post ($0.44) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Catalyst Biosciences’ earnings, with estimates ranging from ($0.64) to ($0.31). Catalyst Biosciences posted earnings per share of ($0.64) during the same quarter last year, which suggests a positive year-over-year growth rate of 31.3%. The business is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Catalyst Biosciences will report full year earnings of ($1.68) per share for the current financial year, with EPS estimates ranging from ($2.87) to ($1.15). For the next year, analysts anticipate that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.64) to ($0.61). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO – Get Rating) last posted its quarterly earnings data on Thursday, March 31st. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.05). Catalyst Biosciences had a negative net margin of 1,200.77% and a negative return on equity of 149.54%.

Separately, Zacks Investment Research cut Catalyst Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, April 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.19.

CBIO remained flat at $$0.38 during trading hours on Friday. The company had a trading volume of 67,878 shares, compared to its average volume of 243,197. The company’s 50-day moving average price is $0.55 and its 200-day moving average price is $0.87. Catalyst Biosciences has a one year low of $0.35 and a one year high of $5.20. The firm has a market capitalization of $11.96 million, a price-to-earnings ratio of -0.15 and a beta of 2.02.

A number of hedge funds and other institutional investors have recently modified their holdings of CBIO. Morgan Stanley raised its position in Catalyst Biosciences by 223.4% during the 1st quarter. Morgan Stanley now owns 59,779 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 41,293 shares in the last quarter. Commonwealth Equity Services LLC bought a new stake in Catalyst Biosciences during the 3rd quarter valued at $41,000. Geode Capital Management LLC raised its position in Catalyst Biosciences by 5.7% during the 3rd quarter. Geode Capital Management LLC now owns 351,541 shares of the biopharmaceutical company’s stock valued at $1,444,000 after purchasing an additional 19,062 shares in the last quarter. Johnson & Johnson bought a new stake in Catalyst Biosciences during the 3rd quarter valued at $275,000. Finally, GSA Capital Partners LLP raised its position in Catalyst Biosciences by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 175,751 shares of the biopharmaceutical company’s stock valued at $722,000 after purchasing an additional 6,216 shares in the last quarter. 62.37% of the stock is owned by institutional investors and hedge funds.

About Catalyst Biosciences (Get Rating)

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system.

Featured Stories